Entering text into the input field will update the search result below

Bristol-Myers Squibb Weakness Offers Opportunity

Jun. 05, 2023 12:24 PM ETBristol-Myers Squibb Company (BMY)7 Comments


  • Bristol-Myers Squibb Company has seen its share price trend down as investors remain concerned about a loss of exclusivity.
  • The company has a strong portfolio of assets, and it's worked hard to de-risk its growth opportunities, with 2025 revenue expected to be $10-15 billion risked.
  • Bristol-Myers Squibb's revenue growth potential is strong, and with reduced debt, we expect the company will be able to drive substantial shareholder returns.
  • The Retirement Forum members get exclusive access to our real-world portfolio. See all our investments here »


E23BMY/iStock via Getty Images

Bristol-Myers Squibb Company (NYSE:BMY) is one of the largest pharmaceutical companies with a market capitalization of more than $130 billion. The company has a dividend yield of more than 3.5%, which combined with its impressive asset

You Only Get 1 Chance To Retire, Join The #1 Retirement Service

The Retirement Forum provides actionable ideals, a high-yield safe retirement portfolio, and macroeconomic outlooks, all to help you maximize your capital and your income. We search the entire market to help you maximize returns. 

Recommendations from a top 0.2% TipRanks author!

Retirement is complicated and you only get once chance to do it right. Don't miss out because you didn't know what was out there.

Only 4% of Americans Are Taking Advantage of This Smart Retirement Move |  The Motley Fool

We provide:

  • Model portfolios to generate high retirement cash flow. 
  • Deep-dive actionable research.
  • Recommendation spreadsheets and option strategies.  

Click for our discounted 2-week free trial!

This article was written by

The Value Portfolio profile picture

The Value Portfolio specializes in building retirement portfolios and utilizes a fact-based research strategy to identify investments. This includes extensive readings of 10Ks, analyst commentary, market reports, and investor presentations. He invests real money in the stocks he recommends.

He is the leader of the investing group The Retirement Forum with features including: model portfolios, macro overviews, in-depth company analysis and retirement planning information. Learn more.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of BMY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (7)

The stock is acting like the patent loss of Eliquis and Optivo will be too much for the new revenue of the slew of recently approved drugs.
That thinking IMO is a big mistake
charged profile picture
In the last twelve months, the biggest single sale by an insider was when the Chairman of the Board & CEO, Giovanni Caforio, sold US$18m worth of shares at a price of US$74.65 per share….listen to his hype as he fills his wallet with cash….he can buy again at the bottom.
Mktneutralhedger profile picture
@charged he's leaving the company on Nov 1
charged profile picture
@Mktneutralhedger saved himself 15% on 18 million…did himself well.
Personal opinions on PFE or BMY? Of course you can have both but at todays price for a long term hold.
ndardick profile picture
I recently added a small amount of BMY in our concentrated portfolio of only 26 stocks to supplement other healthcare investments including CVS and PFE, but I am not convinced that BMY has as much appreciation potential as the other two for many of the reasons you enumerate.
sickkat3 profile picture
I sold BMY after a run-up but it looks like a good time to take another look. Thanks for calling the stock to my attention once again.
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.